Focus: HeartFlow is a public biotechnology company specializing in AI-enabled coronary heart disease assessment, focused on non-invasive diagnostic solutions for coronary artery disease evaluation. The company operates in the high-value cardiovascular diagnostics market with a public market presence (NASDAQ: HTFL).
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
23 added, 24 removed. Backfill posture.
Best fit for commercial, healthcare IT, and early-career professionals seeking growth-stage exposure; less ideal for drug development-focused scientists given diagnostic rather than therapeutic focus.
Flagship AI-enabled coronary computed tomography FFR analysis product driving commercial expansion and clinical validation studies.
Help build intelligence for HeartFlow
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from HeartFlow's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Emerging product line for percutaneous coronary intervention guidance, expanding addressable market within cardiology workflow.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Artificial intelligence-enabled coronary plaque quantification for personalized risk assessment and lipid-lowering therapy: Insights from the FISH&CHIPS study(✰).
Coronary Atherosclerosis in Former NFL Players: A Case Series From the GAMEFILM Registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo